Seelos Therapeutics
New York, US · Nevada corporation · 3 known investors
Founders & leadership
RM
Raj MehraChief Executive Officer
MG
Michael GolembiewskiinChief Financial Officer
BD
BRIAN DORSEYExecutive
CB
CATHERINE BOVENIZERExecutive
NM
NEIL MORTONExecutive
Board
BL
Brian LianBoard director
MD
Margaret DalesandroBoard director
RW
Richard W. PascoeBoard director
RR
RUSTY RAYBoard director
WW
WENDELL WIERENGABoard director
SD
SANDFORD D. SMITHBoard director
KG
KLEANTHIS G. XANTHOPOULOSBoard director
Investors · 3
Also in the syndicate · 2
Lind Global Asset Management V, LLCThe Lind Partners
Funding
SEC filings, press & company announcements$7.3M disclosed across 2 of 8 rounds · 2016–2024
- Undisclosed amountprivate placementNov 2021
Lind Global Asset Management V, LLC, The Lind Partners
Source ↗
▶$1.1MofferedJul 2024 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MofferedJul 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj MehraExecutive Officer
- Brian LianDirector
- Margaret DalesandroDirector
- Michael GolembiewskiExecutive Officer
- Richard W. PascoeDirector
- Offering amount
- $1.1M
- Sales commissions
- $48.7K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$2MofferedMay 2024 · 2 investors · BiotechnologyRule 506(b)
▶$2MofferedMay 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael GolembiewskiExecutive Officer
- Raj MehraExecutive Officer, Director
- Margaret DalesandroDirector
- Brian LianDirector
- Richard W. PascoeDirector
- Offering amount
- $2M
- Sales commissions
- $79.6K
- Finders' fees
- $50K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- May 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.6MofferedFeb 2024 · 3 investors · BiotechnologyRule 506(b)
▶$3.6MofferedFeb 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Margaret DalesandroDirector
- Brian LianDirector
- Daniel J. O'ConnorDirector
- Michael GolembiewskiExecutive Officer
- Raj MehraExecutive Officer, Director
- Richard W. PascoeDirector
- Offering amount
- $3.6M
- Sales commissions
- $280K
- Finders' fees
- $65K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Jan 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$5.6MofferedSep 2020 · 13 investors · BiotechnologyRule 506(b)
▶$5.6MofferedSep 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Judith DunnDirector
- Daniel J. O'ConnorDirector
- Richard W. PascoeDirector
- Brian LianDirector
- Raj MehraExecutive Officer, Director
- Offering amount
- $5.6M
- Sales commissions
- $490.2K
- Finders' fees
- $80K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Sep 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4MofferedAug 2019 · 9 investors · BiotechnologyRule 506(b)
▶$4MofferedAug 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raj MehraExecutive Officer, Director
- Brian LianDirector
- Richard W. PascoeDirector
- Robin L. SmithDirector
- Daniel J. O'ConnorDirector
- Offering amount
- $4M
- Sales commissions
- $469.9K
- Finders' fees
- $80K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.7MraisedSep 2017 · 9 investors · PharmaceuticalsRule 506(c)
▶$3.7MraisedSep 2017 · 9 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- WENDELL WIERENGADirector
- SANDFORD D. SMITHDirector
- NEIL MORTONExecutive Officer
- RUSTY RAYDirector
- BRIAN DORSEYExecutive Officer
- PAUL V. MAIERDirector
- KLEANTHIS G. XANTHOPOULOSDirector
- RICHARD W. PASCOEExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Sales commissions
- $258.4K
- Placement agents
- H.C. WAINWRIGHT & CO., LLC
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
▶$3.7MraisedOct 2016 · 2 investors · PharmaceuticalsRule 506(c)
▶$3.7MraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- BRIAN DORSEYExecutive Officer
- RUSTY RAYDirector
- CATHERINE BOVENIZERExecutive Officer
- WENDELL WIERENGADirector
- SANDFORD D. SMITHDirector
- KLEANTHIS G. XANTHOPOULOSDirector
- NEIL MORTONExecutive Officer
- RICHARD W. PASCOEExecutive Officer, Director
- PAUL V. MAIERDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Sales commissions
- $327.5K
- Placement agents
- RODMAN & RENSHAW LLC
- First sale
- Sep 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapApplied Therapeutics10 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Elicio10 shared keywordsElicio Therapeutics is a biopharmaceutical company focused on developing therapeutic treatments.
Xilio Therapeutics9 shared keywordsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
Lexeotx9 shared keywordsLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
Exelixis8 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Solu7 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Seelos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who founded Seelos Therapeutics?
- Seelos Therapeutics was founded by Raj Mehra.
- Who are Seelos Therapeutics's investors?
- Seelos Therapeutics's investors include Altium Capital.
- How much funding has Seelos Therapeutics raised?
- Seelos Therapeutics has disclosed $7.3M raised across 2 of its 8 known rounds.
- Where is Seelos Therapeutics headquartered?
- Seelos Therapeutics is headquartered in New York, US.